Key Takeaways:
Law firm Lowey Dannenberg P.C. has launched an investigation into Fulgent Genetics Inc. (NASDAQ: FLGT) for potential securities law violations after the company missed its 2025 revenue guidance.
"On February 27, 2026, Fulgent reported its fourth quarter and full year 2025 financial results," Lowey Dannenberg said in a statement issued May 8. The firm is encouraging investors who suffered losses in the company's securities to come forward.
The company disclosed that full-year 2025 revenue was approximately $322.7 million, which fell slightly short of its previously updated guidance. Fulgent also reported that its fourth-quarter revenue declined sequentially. The specific guidance figures and the magnitude of the revenue miss were not detailed in the law firm's announcement.
The investigation raises the risk of a class-action lawsuit, which could expose Fulgent to financial penalties and damage its reputation with investors. The outcome will depend on whether the firm's disclosures regarding its financial performance and prospects are found to have been materially false or misleading.
Lowey Dannenberg is a national law firm that represents institutional and individual investors in cases involving corporate fraud and malfeasance. The firm has a track record of recovering significant sums for investors in securities-related lawsuits. Investors who wish to learn more about the investigation can contact attorneys Andrea Farah or Vincent R. Cappucci Jr.
The investigation introduces a new layer of legal risk for Fulgent shareholders on top of concerns about the company's growth trajectory. Investors will be closely watching for any formal lawsuit filing and the company's official response to the allegations.
This article is for informational purposes only and does not constitute investment advice.
